TOKYO, May 18, 2023 – (JCN Newswire) – Fujitsu today announced the commercial debut of its “Biodrug Design Accelerator,” a platform to manage research processes for peptide (1) drug discovery, which many regard as a promising frontier in the field of new drug development. Fujitsu launched the new platform to pharmaceutical companies in Japan on May 18 with plans to expand the offering to the global market in the third quarter of fiscal 2023.The new platform represents part of Fujitsu’s ongoing efforts to contribute to the creation of a healthy society as part of its vision for “Healthy Living” under Fujitsu Uvance.Biodrug Design Accelerator will support peptide drug discovery scientists in pharmaceutical companies to accelerate and improve the efficiency of peptide drug development…
Read More
About The Author
